Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)
Eli Lilly shares closed at $1,027.51 Friday, up about 3% for the week after late-stage trial data showed its obesity drug retatrutide delivered nearly 29% average weight loss in patients with knee osteoarthritis. The stock rebounded from an early-week dip, outperforming the broader market as investors weighed drug tolerability and future pricing strategy.